Precision Optics (US:POCI)2025-05-15 22:00Financial Data and Key Metrics Changes - For Q3 2025, revenue was $4.2 million, down from $5.2 million in Q3 2024. Production revenue increased to $3.2 million from $3 million, while engineering revenue decreased to $924,000 from $2.3 million [21][24] - Gross margins fell to 10% from 35% year-over-year, attributed to low yields and a one-month shutdown of production lines [23] - The net loss for the quarter was $2.1 million compared to a net loss of $317,000 in the same quarter last year. Adjusted EBITDA was negative $1.3 million, down from a positive $52,000 [24] Business Line Data and Key Metrics Changes - The single-use cystoscope program faced significant yield issues, dropping to less than 50% before corrective actions were taken [8] - Systems production revenue, including new and legacy products, grew over 20% quarter-over-quarter and more than doubled year-over-year [10] - Aerospace program production revenue increased from approximately $300,000 in Q1 to just under $900,000 in Q3, with expectations for further growth in Q4 [11] Market Data and Key Metrics Changes - The single-use endoscope market is growing at annual rates estimated to be as high as 20%, driven by lower costs and superior performance of new technologies [15][16] - The company has a production backlog exceeding $6 million, indicating strong demand for its products [12] Company Strategy and Development Direction - The company is focused on resolving production challenges and expanding its Unity platform, which aims to streamline the development of new endoscopic systems [17] - The Unity platform is designed to reduce risk, cost, and time to market, with positive responses from potential customers [18] - The company is committed to leveraging its proprietary manufacturing technology and partnerships to become a leading supplier in the single-use endoscope market [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming production challenges and anticipates significant revenue growth in Q4, aiming for $6 million in sales [26] - The company expects to achieve positive adjusted EBITDA in the upcoming quarter, indicating a recovery from recent setbacks [43] Other Important Information - The company has made changes to its Board, adding two new members with relevant experience in the medical device industry [19][20] - The company is actively pursuing alternative suppliers to mitigate the impact of tariffs on its business [68][69] Q&A Session Summary Question: Were engineering resources diverted to fix production issues? - Yes, engineering resources were used to address production challenges, impacting billable projects [30][31] Question: Will the aerospace program continue beyond 2026? - The aerospace program is expected to continue beyond 2026, with minimum annual purchase commitments of nearly $4 million for 2025 and 2026 [32][33] Question: Are there any contractual issues due to production delays? - There are no contractual issues; the customer has been supportive and has even placed additional orders [35][38] Question: Is the company fully staffed for production? - The company is close to full staffing for assembly technicians and is looking to add a few more to ensure smooth operations [39] Question: When will the second production line be operational? - The second production line is expected to start running in the first half of fiscal 2026 [40] Question: Will the current quarter be EBITDA positive? - Yes, the expectation is for the current quarter to be EBITDA positive, reducing the need for additional stock issues [43]